Jacqueline M Shuplock1, Andrew H Smith2, Jill Owen2, Sara L Van Driest2, Matt Marshall2, Benjamin Saville2, Meng Xu2, Andrew E Radbill2, Frank A Fish2, Prince J Kannankeril2. 1. From the Thomas P. Graham Jr. Division of Pediatric Cardiology (J.M.S., A.H.S., J.O., A.E.R., F.A.F., P.J.K.), Division of Pediatric Critical Care Medicine (A.H.S.), and Division of General Pediatrics (S.L.V.D.), Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; Department of Pharmaceutical Services at Vanderbilt University Medical Center, Nashville, TN (M.M.); and Department of Biostatistics at Vanderbilt University School of Medicine, Nashville, TN (B.S., M.X.). jacqueline.m.shuplock@vanderbilt.edu. 2. From the Thomas P. Graham Jr. Division of Pediatric Cardiology (J.M.S., A.H.S., J.O., A.E.R., F.A.F., P.J.K.), Division of Pediatric Critical Care Medicine (A.H.S.), and Division of General Pediatrics (S.L.V.D.), Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; Department of Pharmaceutical Services at Vanderbilt University Medical Center, Nashville, TN (M.M.); and Department of Biostatistics at Vanderbilt University School of Medicine, Nashville, TN (B.S., M.X.).
Abstract
BACKGROUND: Dexmedetomidine is commonly used after congenital heart surgery and may be associated with a decreased incidence of postoperative tachyarrhythmias. Using a large cohort of patients undergoing congenital heart surgery, we examined for an association between dexmedetomidine use in the immediate postoperative period and subsequent arrhythmia development. METHODS AND RESULTS: A total of 1593 surgical procedures for congenital heart disease were performed. Dexmedetomidine was administered in the immediate postoperative period after 468 (29%) surgical procedures. When compared with 1125 controls, the group receiving dexmedetomidine demonstrated significantly fewer tachyarrhythmias (29% versus 38%; P<0.001), tachyarrhythmias receiving intervention (14% versus 23%; P<0.001), bradyarrhythmias (18% versus 22%; P=0.03), and bradyarrhythmias receiving intervention (12% versus 16%; P=0.04). After propensity score matching with 468 controls, the arrhythmia incidence between groups became similar: tachyarrhythmias (29% versus 31%; P=0.66), tachyarrhythmias receiving intervention (14% versus 17%; P=0.16), bradyarrhythmias (18% versus 15%; P=0.44), and bradyarrhythmias receiving intervention (12% versus 9%; P=0.17). After excluding controls exposed to dexmedetomidine at a later time in the hospitalization, dexmedetomidine was associated with increased odds of bradyarrhythmias receiving intervention (odds ratio, 2.18; 95% confidence interval, 1.02-4.65). Furthermore, there was a dose-dependent increase in the odds of bradyarrhythmias (odds ratio, 1.04; 95% confidence interval, 1.01-1.07) and bradyarrhythmias receiving intervention (odds ratio, 1.05; 95% confidence interval, 1.01-1.08). CONCLUSIONS: Although dexmedetomidine exposure in the immediate postoperative period is not associated with a clinically meaningful difference in the incidence of tachyarrhythmias after congenital heart surgery, it may be associated with increased odds of bradyarrhythmias.
BACKGROUND:Dexmedetomidine is commonly used after congenital heart surgery and may be associated with a decreased incidence of postoperative tachyarrhythmias. Using a large cohort of patients undergoing congenital heart surgery, we examined for an association between dexmedetomidine use in the immediate postoperative period and subsequent arrhythmia development. METHODS AND RESULTS: A total of 1593 surgical procedures for congenital heart disease were performed. Dexmedetomidine was administered in the immediate postoperative period after 468 (29%) surgical procedures. When compared with 1125 controls, the group receiving dexmedetomidine demonstrated significantly fewer tachyarrhythmias (29% versus 38%; P<0.001), tachyarrhythmias receiving intervention (14% versus 23%; P<0.001), bradyarrhythmias (18% versus 22%; P=0.03), and bradyarrhythmias receiving intervention (12% versus 16%; P=0.04). After propensity score matching with 468 controls, the arrhythmia incidence between groups became similar: tachyarrhythmias (29% versus 31%; P=0.66), tachyarrhythmias receiving intervention (14% versus 17%; P=0.16), bradyarrhythmias (18% versus 15%; P=0.44), and bradyarrhythmias receiving intervention (12% versus 9%; P=0.17). After excluding controls exposed to dexmedetomidine at a later time in the hospitalization, dexmedetomidine was associated with increased odds of bradyarrhythmias receiving intervention (odds ratio, 2.18; 95% confidence interval, 1.02-4.65). Furthermore, there was a dose-dependent increase in the odds of bradyarrhythmias (odds ratio, 1.04; 95% confidence interval, 1.01-1.07) and bradyarrhythmias receiving intervention (odds ratio, 1.05; 95% confidence interval, 1.01-1.08). CONCLUSIONS: Although dexmedetomidine exposure in the immediate postoperative period is not associated with a clinically meaningful difference in the incidence of tachyarrhythmias after congenital heart surgery, it may be associated with increased odds of bradyarrhythmias.
Authors: Constantinos Chrysostomou; Victor O Morell; Peter Wearden; Joan Sanchez-de-Toledo; Edmund H Jooste; Lee Beerman Journal: Congenit Heart Dis Date: 2012-05-22 Impact factor: 2.007
Authors: Constantinos Chrysostomou; Joan Sanchez-de-Toledo; Peter Wearden; Edmund H Jooste; Steven E Lichtenstein; Patrick M Callahan; Tunga Suresh; Elizabeth O'Malley; Dana Shiderly; Jamie Haney; Masahiro Yoshida; Richard Orr; Ricardo Munoz; Victor O Morell Journal: Ann Thorac Surg Date: 2011-09 Impact factor: 4.330
Authors: Constantinos Chrysostomou; Lee Beerman; Dana Shiderly; Donald Berry; Victor O Morell; Ricardo Munoz Journal: Anesth Analg Date: 2008-11 Impact factor: 5.108
Authors: Jeffrey P Moak; Patricio Arias; Jonathan R Kaltman; Yao Cheng; Robert McCarter; Sridhar Hanumanthaiah; Gerard R Martin; Richard A Jonas Journal: Pacing Clin Electrophysiol Date: 2013-05-10 Impact factor: 1.976
Authors: Venu Amula; David F Vener; Charles G Pribble; Lori Riegger; Elizabeth C Wilson; Lara S Shekerdemian; Zhining Ou; Angela P Presson; Madolin K Witte; Susan C Nicolson Journal: Pediatr Crit Care Med Date: 2019-10 Impact factor: 3.624
Authors: Eric J Hall; Andrew H Smith; Frank A Fish; David P Bichell; Bret A Mettler; Kimberly Crum; Prince J Kannankeril; Andrew E Radbill Journal: Ann Thorac Surg Date: 2017-09-28 Impact factor: 4.330
Authors: Nathan T James; Joseph H Breeyear; Richard Caprioli; Todd Edwards; Brian Hachey; Prince J Kannankeril; Jacob M Keaton; Matthew D Marshall; Sara L Van Driest; Leena Choi Journal: Br J Clin Pharmacol Date: 2022-01-28 Impact factor: 3.716
Authors: Leena Choi; Cole Beck; Elizabeth McNeer; Hannah L Weeks; Michael L Williams; Nathan T James; Xinnan Niu; Bassel W Abou-Khalil; Kelly A Birdwell; Dan M Roden; C Michael Stein; Cosmin A Bejan; Joshua C Denny; Sara L Van Driest Journal: Clin Pharmacol Ther Date: 2020-02-11 Impact factor: 6.875